The founders of Latona Therapeutics are biomedical engineering Ph.D. students and MBA students from the Illinois Institute of Technology and University of Chicago, respectively. The team is equipped with a wealth of knowledge in the fundamentals of biomaterials and drug delivery as well as extensive industry experience in medical device development. The founding team is also augmented with a thoughtfully selected group of experienced industry advisors with specialized expertise in drug development, oncology, and strategic development of life science startups.
Latona Therapeutics was founded from a common passion for improving treatment options for cancer patients. Since the team has entered the Nanotechnology Startup Challenge in Cancer competition, it has been a long but rewarding journey. Interactions with Latona’s clinical and industry advisors have built upon the training provided by The Center for Advancing Innovation and expanded Latona’s understanding of the cancer treatment industry. One of the competition’s main challenges was identifying a sizable and underserved market which our technology was best suited to treat. Extensive research of current cancer therapies, coupled with discussions with our clinical advisors, led us to adapt Latona’s technology for neoadjuvant chemotherapy in triple negative breast cancer treatment.
The next step for Latona is to secure a license from the National Institutes of Health for the photoactivatable liposome patent. Latona also plans to participate in additional startup competitions in order to receive more feedback from experts in relevant fields. Furthermore, Latona is prepared to pursue SBIR grants and other non-dilutive funding opportunities. Our spirits are high at Latona Therapeutics as we continue our journey of bringing better treatment to cancer patients. - Yusheng He, Latona Therapeutics
Latona Therapeutics was founded from a common passion for improving treatment options for cancer patients. Since the team has entered the Nanotechnology Startup Challenge in Cancer competition, it has been a long but rewarding journey. Interactions with Latona’s clinical and industry advisors have built upon the training provided by The Center for Advancing Innovation and expanded Latona’s understanding of the cancer treatment industry. One of the competition’s main challenges was identifying a sizable and underserved market which our technology was best suited to treat. Extensive research of current cancer therapies, coupled with discussions with our clinical advisors, led us to adapt Latona’s technology for neoadjuvant chemotherapy in triple negative breast cancer treatment.
The next step for Latona is to secure a license from the National Institutes of Health for the photoactivatable liposome patent. Latona also plans to participate in additional startup competitions in order to receive more feedback from experts in relevant fields. Furthermore, Latona is prepared to pursue SBIR grants and other non-dilutive funding opportunities. Our spirits are high at Latona Therapeutics as we continue our journey of bringing better treatment to cancer patients. - Yusheng He, Latona Therapeutics
RSS Feed
